Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $500.47 million
- Book Value:
- Revenue TTM:
- $313.79 million
- Operating Margin TTM:
- Gross Profit TTM:
- $202.52 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Artivion Inc had its IPO on 1993-02-12 under the ticker symbol AORT.
The company operates in the Healthcare sector and Medical Devices industry. Artivion Inc has a staff strength of 1,300 employees.
Shares of Artivion Inc opened at $11.61 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $11.6 - $11.96, and closed at $11.93.
This is a +1.53% increase from the previous day's closing price.
A total volume of 91,647 shares were traded at the close of the day’s session.
In the last one week, shares of Artivion Inc have slipped by -2.69%.
Artivion Inc's Key Ratios
Artivion Inc has a market cap of $500.47 million, indicating a price to book ratio of 2.0504 and a price to sales ratio of 1.6348.
In the last 12-months Artivion Inc’s revenue was $313.79 million with a gross profit of $202.52 million and an EBITDA of $37.64 million. The EBITDA ratio measures Artivion Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Artivion Inc’s operating margin was 4.84% while its return on assets stood at 1.22% with a return of equity of -6.56%.
In Q4, Artivion Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Artivion Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.47 per share while it has a forward price to earnings multiple of 357.1429 and a PEG multiple of 181.5. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Artivion Inc’s profitability.
Artivion Inc stock is trading at a EV to sales ratio of 2.6807 and a EV to EBITDA ratio of 156.2629. Its price to sales ratio in the trailing 12-months stood at 1.6348.
Artivion Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $762.80 million
- Total Liabilities
- $49.68 million
- Operating Cash Flow
- Capital Expenditure
- $2.67 million
- Dividend Payout Ratio
Artivion Inc ended 2023 with $762.80 million in total assets and $0 in total liabilities. Its intangible assets were valued at $762.80 million while shareholder equity stood at $284.33 million.
Artivion Inc ended 2023 with $29.97 million in deferred long-term liabilities, $49.68 million in other current liabilities, 418000.00 in common stock, $-17217000.00 in retained earnings and $243.63 million in goodwill. Its cash balance stood at $39.35 million and cash and short-term investments were $39.35 million. The company’s total short-term debt was $5,429,000 while long-term debt stood at $306.50 million.
Artivion Inc’s total current assets stands at $247.33 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $69.58 million compared to accounts payable of $12.00 million and inventory worth $74.48 million.
In 2023, Artivion Inc's operating cash flow was $-2668000.00 while its capital expenditure stood at $2.67 million.
Comparatively, Artivion Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Artivion Inc stock is currently trading at $11.93 per share. It touched a 52-week high of $23.43 and a 52-week low of $23.43. Analysts tracking the stock have a 12-month average target price of $22.58.
Its 50-day moving average was $12.85 and 200-day moving average was $15.3 The short ratio stood at 28.41 indicating a short percent outstanding of 0%.
Around 497% of the company’s stock are held by insiders while 8749.7% are held by institutions.
Frequently Asked Questions About Artivion Inc
Similar Industry Stocks (Medical Devices)
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent and graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.